NO20054662L - Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre - Google Patents

Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre

Info

Publication number
NO20054662L
NO20054662L NO20054662A NO20054662A NO20054662L NO 20054662 L NO20054662 L NO 20054662L NO 20054662 A NO20054662 A NO 20054662A NO 20054662 A NO20054662 A NO 20054662A NO 20054662 L NO20054662 L NO 20054662L
Authority
NO
Norway
Prior art keywords
fluoroaniline
chloro
methyl
phenylacetic acid
pharmaceutical composition
Prior art date
Application number
NO20054662A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054662D0 (no
Inventor
Maha Y Khaled
Patrick Forenzo
Barbara Wang
Joseph Lawrence Zielinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054662(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20054662D0 publication Critical patent/NO20054662D0/no
Publication of NO20054662L publication Critical patent/NO20054662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20054662A 2003-03-12 2005-10-11 Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre NO20054662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12
PCT/EP2004/002528 WO2004080451A1 (fr) 2003-03-12 2004-03-11 Composition pharmaceutique contenant de l'acide 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetique

Publications (2)

Publication Number Publication Date
NO20054662D0 NO20054662D0 (no) 2005-10-11
NO20054662L true NO20054662L (no) 2005-12-05

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054662A NO20054662L (no) 2003-03-12 2005-10-11 Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre

Country Status (29)

Country Link
US (2) US20060094787A1 (fr)
EP (1) EP1603550B1 (fr)
JP (1) JP4580921B2 (fr)
KR (1) KR20050109077A (fr)
CN (1) CN100345536C (fr)
AR (1) AR043536A1 (fr)
AT (1) ATE418332T1 (fr)
AU (1) AU2004218921B2 (fr)
BR (1) BRPI0408270A (fr)
CA (1) CA2518393A1 (fr)
CL (1) CL2004000496A1 (fr)
DE (1) DE602004018622D1 (fr)
EC (1) ECSP055998A (fr)
ES (1) ES2318277T3 (fr)
HR (1) HRP20050787A2 (fr)
IL (1) IL170518A (fr)
IS (1) IS2658B (fr)
MA (1) MA27670A1 (fr)
MX (1) MXPA05009686A (fr)
MY (1) MY139455A (fr)
NO (1) NO20054662L (fr)
NZ (1) NZ542218A (fr)
PE (1) PE20041063A1 (fr)
PT (1) PT1603550E (fr)
RU (1) RU2363462C2 (fr)
TN (1) TNSN05222A1 (fr)
TW (1) TWI327913B (fr)
WO (1) WO2004080451A1 (fr)
ZA (1) ZA200506750B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003929A (es) * 2003-10-08 2006-07-05 Novartis Ag Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino) -fenilacetico.
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
EP2316422A1 (fr) * 2007-11-12 2011-05-04 Novartis AG Compositions pharmaceutiques liquides contenant du valsartan
EP2926810A1 (fr) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations pharmaceutiques liquides orales de loxoprophène
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP4755373A1 (fr) 2016-09-09 2026-06-10 Azurity Pharmaceuticals, Inc. Suspensions et diluants de metronidazole et de baclofene
WO2018237327A1 (fr) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
EP3687501A4 (fr) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AU2003207453A1 (en) * 2002-01-07 2003-07-24 Pharmacia Corp Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
EP1497268A4 (fr) * 2002-04-05 2006-01-18 Nitromed Inc Donneurs de monoxyde d'azote, compositions et procedes d'utilisation, applications correspondantes

Also Published As

Publication number Publication date
US20060094787A1 (en) 2006-05-04
JP2006519811A (ja) 2006-08-31
HK1086492A1 (en) 2006-09-22
DE602004018622D1 (de) 2009-02-05
RU2005131310A (ru) 2006-05-10
KR20050109077A (ko) 2005-11-17
IL170518A (en) 2010-11-30
US20090048344A1 (en) 2009-02-19
WO2004080451A1 (fr) 2004-09-23
CN1756541A (zh) 2006-04-05
CN100345536C (zh) 2007-10-31
AR043536A1 (es) 2005-08-03
TW200505429A (en) 2005-02-16
ATE418332T1 (de) 2009-01-15
ECSP055998A (es) 2006-01-27
EP1603550B1 (fr) 2008-12-24
HRP20050787A2 (en) 2006-12-31
TNSN05222A1 (en) 2007-06-11
PT1603550E (pt) 2009-03-20
NO20054662D0 (no) 2005-10-11
MXPA05009686A (es) 2005-10-20
TWI327913B (en) 2010-08-01
NZ542218A (en) 2009-01-31
MA27670A1 (fr) 2005-12-01
EP1603550A1 (fr) 2005-12-14
RU2363462C2 (ru) 2009-08-10
JP4580921B2 (ja) 2010-11-17
BRPI0408270A (pt) 2006-03-07
AU2004218921A1 (en) 2004-09-23
CA2518393A1 (fr) 2004-09-23
CL2004000496A1 (es) 2005-01-14
ZA200506750B (en) 2007-02-28
PE20041063A1 (es) 2005-03-07
MY139455A (en) 2009-10-30
IS2658B (is) 2010-08-15
IS8049A (is) 2005-09-28
AU2004218921B2 (en) 2007-05-17
ES2318277T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
NO20054848L (no) Substituerte p-diaminobenzenderivater
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20055219L (no) Nye forbindelser
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
NO20081844L (no) Terapeutiske forbindelser
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
AP2001002217A0 (fr) Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
NO20062355L (no) Sammensetninger for behandling av sykdom i munnhulen og ovre andedrettssystem
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006100081A3 (fr) Derives d'indoxyle substitues, medicaments les contenant et leur utilisation
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HRP20050787A2 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application